KTTA Stock Summary and Trading Ideas (Pasithea Therapeutics Corp. | NASDAQ:KTTA)

Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. Its pipeline includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module).

Pasithea Therapeutics Corp. trades on the NASDAQ stock market under the symbol KTTA.

As of March 31, 2026, KTTA stock price climbed to $0.74 with 93,768 million shares trading.

KTTA has a beta of 3.76, meaning it tends to be more sensitive to market movements. KTTA has a correlation of 0.10 to the broad based SPY ETF.

KTTA has a market cap of $16.62 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, KTTA traded as high as $17.40 and as low as $.28.

The top ETF exchange traded funds that KTTA belongs to (by Net Assets): PSIL, VXF.

KTTA has underperformed the market in the last year with a price return of -44.6% while the SPY ETF gained +18.4%. KTTA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.5% and -10.2%, respectively, while the SPY returned -5.1% and -2.5%, respectively.

KTTA support price is $.68 and resistance is $.75 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KTTA shares will trade within this expected range on the day.